Overview of pharmacotherapy targeting COVID-19 disease based on ACE-2: current challenges and future directions

The new Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) triggered the pandemic of COVID-19, which is currently still ongoing. In 2021 a worldwide vaccine campaign was launched, and in parallel the lines of research are continuing to target the most effective drug therapies for the treatment of COVID-19 disease. SARS-CoV-2 enters host cells via glycoprotein angiotensin-converting enzyme 2 (ACE-2), which plays a major role in renin-angiotensin system interactions and undergoes changes in expression during metabolic and viral diseases, including COVID-19. It seems that the severe lung damage that occurs in several cases of COVID-19 disease may be connected to a deregulated expression of ACE-2. In this manuscript we focus on the line of research that studies the pharmacological modification of ACE-2 expression, a promising weapon to counter the severe harms caused by COVID-19.

Automated summary

This article discusses the research progress in using drugs to modify ACE-2 expression to counter COVID-19, pointing out the potential connection between severe respiratory diseases and deregulated ACE-2 expression.